The Covid-19 pandemic prompted increased digitalisation in healthcare, exposing a greater potential attack surface. Credit: Photoroyalty / Shutterstock.

Abbott has reported total worldwide sales of $10.37bn for the second quarter (Q2) of 2024, as against $9.97bn in Q2 last year, up 4% on a reported basis and 7.4% on an organic basis.

However, the company’s net earnings saw a slight decline of 5.3% to $1.30bn in Q2 2024, down from $1.37bn in the previous year’s quarter.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Abbott’s worldwide medical devices segment reported a significant increase of 10.2% on a reported basis and 12.1% on an organic basis, with robust growth in both the US and international markets.

The company’s diagnostics division experienced a downturn in Covid-19 testing-related sales, which fell to $102m in Q2 2024 from $263m in the same quarter of the previous year.

Excluding these sales, Abbot’s global diagnostics sales increased by 1.8% on a reported basis and 5.9% on an organic basis.

See Also:

The core laboratory diagnostics segment, in particular, saw a 3% reported increase and an 8.8% organic increase, driven by the strong adoption of Abbott’s Alinity family of diagnostics systems.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This surge was attributed to double-digit growth in diabetes care, electrophysiology, and structural heart, with newly launched products, including TriClip, Navitor, and AVEIR.

Looking ahead, Abbott has raised its full-year 2024 earnings per share (EPS) guidance range, projecting a GAAP [generally accepted accounting principles] basis EPS of $3.30 to $3.40 and an adjusted EPS of $4.61 to $4.71.

Additionally, the company has refined its full-year 2024 organic sales growth guidance, excluding Covid-19 testing-related sales, to a range of 9.5% to 10%.

Abbott chairman and CEO Robert Ford said: “We achieved another quarter of strong growth in our underlying base business.

“We have a lot of positive momentum heading into the second half of the year and are raising our full-year guidance.”

Last month, the US Food and Drug Administration approved Abbott’s Lingo and Libre Rio over-the-counter continuous glucose monitoring systems.